Core Viewpoint - He Yuan Bio is expected to report a net loss of between 143 million to 167 million yuan for the year 2025, indicating ongoing financial challenges despite product launches and revenue growth [1] Financial Performance - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -191 million to -162 million yuan for 2025 [1] - The overall performance remains in a loss state during the reporting period due to various factors [1] Product Development - The product "Aofumin" (recombinant human albumin injection) has been approved for market entry, contributing to rapid revenue growth [1] - The production line for the annual output of 10 tons of recombinant human albumin is still in the capacity ramp-up phase, with gradual capacity release expected [1] Research and Development - The company continues to maintain high levels of investment in research and development [1]
禾元生物：预计2025年全年净亏损1.43亿元—1.67亿元